I was surprised some on the FDA review board already weighed in on Geron's application before the actual review. Thought that was a no-no??
>>The regulator said more treatment-emergent adverse events, serious adverse events and events leading to dose modification were observed in the imetelstat group compared to placebo in a phase 3 study in certain patients with myelodysplastic syndrome.
Nemee, Sweet of you to show up at the last minute to save us all! Your team is not getting very good press coverage today:
Denial of the Motion to Dismiss in Northwest Biotherapeutics Lawsuit Against Seven Wall Street Market Makers for Spoofing Would be a Major Catalyst for the Company
No one can say that I did not at least try to help investors here, but, we are all grownups. Cautionary Advice can can only be given so many times , I suppose ☝️🤷🏻♂️🇬🇧
Gee let me go sell all my shares of NWBO because one random wanker on the internet told me he cared for me and didn’t want me to lose money. Do you know how stupid you sound?